EXHIBIT 99.2
Published on May 1, 2017
FINANCIAL
SUPPLEMENT
NYSE: CIM
1st Quarter 2017
Information is unaudited, estimated and subject to change.
DISCLAIMER This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the UnitedStates Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates andprojections and, consequently, readers should not rely on these forward-looking statements as predictions of future
events. Words such as “goal” “expect,” “target,” “assume,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,”
“may,” “will,” “could,” “should,” “believe,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify
such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that
could cause actual results to differ materially from expected results, including, among other things, those described in
our Annual Report on Form 10-K for the year ended December 31, 2016, and any subsequent Quarterly Reports on Form
10-Q, under the caption “Risk Factors.” Factors that could cause actual results to differ include, but are not limited to: the
state of credit markets and general economic conditions; changes in interest rates and the market value of our assets;
the rates of default or decreased recovery on the mortgages underlying our target assets; the occurrence, extent and
timing of credit losses within our portfolio; the credit risk in our underlying assets; declines in home prices; our ability to
establish, adjust and maintain appropriate hedges for the risks in our portfolio; the availability and cost of our target
assets; our ability to borrow to finance our assets and the associated costs; changes in the competitive landscape within
our industry; our ability to manage various operational risks and costs associated with our business; interruptions in or
impairments to our communications and information technology systems; our ability to acquire residential mortgage
loans and successfully securitize the residential mortgage loans we acquire; our ability to oversee our third party sub-
servicers; the impact of any deficiencies in the servicing or foreclosure practices of third parties and related delays in the
foreclosure process; our exposure to legal and regulatory claims; legislative and regulatory actions affecting our
business; the impact of new or modified government mortgage refinance or principal reduction programs; our ability to
maintain our REIT qualification; and limitations imposed on our business due to our REIT status and our exempt status
under the Investment Company Act of 1940.
Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the
date made. Chimera does not undertake or accept any obligation to release publicly any updates or revisions to any
forward-looking statement to reflect any change in its expectations or any change in events, conditions or
circumstances on which any such statement is based. Additional information concerning these and other risk factors is
contained in Chimera’s most recent filings with the Securities and Exchange Commission (SEC). All subsequent written
and oral forward-looking statements concerning Chimera or matters attributable to Chimera or any person acting on its
behalf are expressly qualified in their entirety by the cautionary statements above.
This presentation may include industry and market data obtained through research, surveys, and studies conducted by
third parties and industry publications. We have not independently verified any such market and industry data from
third-party sources. This presentation is provided for discussion purposes only and may not be relied upon as legal or
investment advice, nor is it intended to be inclusive of all the risks and uncertainties that should be considered. This
presentation does not constitute an offer to purchase or sell any securities, nor shall it be construed to be indicative of
the terms of an offer that the parties or their respective affiliates would accept.
Readers are advised that the financial information in this presentation is based on company data available at the time of
this presentation and, in certain circumstances, may not have been audited by the company’s independent auditors.
Information is unaudited, estimated and subject to change. 2
PORTFOLIO COMPOSITION
Residential
Mortgage Credit
Portfolio
Agency
Portfolio Total Portfolio
Gross Asset Yield: 7.7% 3.0% 6.5%
Financing Cost(2): 4.1% 1.5% 3.5%
Net Interest
Spread: 3.6% 1.5% 3.0%
Net Interest
Margin: 4.1% 1.7% 3.6%
All data as of March 31, 2017
(1) Financing excludes unsettled trades.
(2) Includes the interest incurred on interest rate swaps.
Net Investment Analysis
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
B
ill
io
ns
$2.9
$0.7
$2.8
$3.1
$10.4
Non-Recourse
(Securitization)
Recourse (Repo)
Recourse (Repo)
Equity
Equity
Agency Portfolio
Total Assets: 4.1 billion(1)
Residential Mortgage
Credit Portfolio
Total Assets: 15.9 billion(1)
81% of Chimera's equity capital is allocated to mortgage credit
Information is unaudited, estimated and subject to change. 3
March 31, 2017 December 31, 2016
Total Portfolio: $20.0 billion Total Portfolio: $16.3 billion
Non-Agency MBS Agency MBS
Securitized Loan Portfolio
16%
20%
63%
Non-Agency MBS Agency MBS
Securitized Loan Portfolio
20%
26%
54%
GAAP ASSET ALLOCATION(1)
(1) Based on fair value.
Chimera sponsored four residential mortgage loan securitizations totaling $4.1 billion
Information is unaudited, estimated and subject to change. 4
March 31, 2017 December 31, 2016
Total Financing: $16.3 Billion Total Financing: $12.9 Billion
Agency Repurchase Agreements, RMBS
Non-Agency Repurchase Agreements, RMBS
Non-Recourse Debt, Securitized RMBS and Loans (2)
19%
17%
64%
Agency Repurchase Agreements, RMBS
Non-Agency Repurchase Agreements, RMBS
Non-Recourse Debt, Securitized RMBS and Loans (2)
24%
20%
57%
GAAP FINANCING SOURCES
(1) Leverage ratios as of March 31, 2017
(2) Consists of tranches of RMBS and loan securitizations sold to third parties.
Total Leverage(1): 4.6:1
Recourse Leverage(1): 1.7:1
Information is unaudited, estimated and subject to change. 5
($ in thousands) At Issuance / Acquisition March 31, 2017
Vintage Deal Total OriginalFace
Total of
Tranches
Sold
Total of
Tranches
Retained
Total Remaining
Face
Remaining
Face of
Tranches
Sold
Remaining Face
of Tranches
Retained
2017 CIM 2017-4 $830,510 $710,003 $120,507 $830,510 $710,003 $120,507
2017 CIM 2017-3 2,434,640 2,113,267 321,373 2,434,640 2,113,267 321,373
2017 CIM 2017-2 331,440 248,580 82,860 331,440 248,580 82,860
2017 CIM 2017-1 526,267 368,387 157,880 515,939 358,236 157,703
2016 CIM 2016-FRE1 185,811 115,165 70,646 179,854 109,118 70,736
2016 CIM 2016-5(1) 66,171 10,000 56,171 57,506 8,863 48,643
2016 CIM 2016-4(1) 601,733 493,420 108,313 569,077 457,005 112,072
2016 CIM 2016-3 1,746,084 1,478,933 267,151 1,548,716 1,279,658 269,058
2016 CIM 2016-2 1,762,177 1,492,563 269,614 1,560,763 1,289,348 271,415
2016 CIM 2016-1 1,499,341 1,266,898 232,443 1,318,596 1,085,591 233,005
2015 CIM 2015-4AG(2) 750,647 425,000 325,647 598,060 403,083 194,977
2015 CIM 2015-3AG(3) 698,812 520,935 177,877 531,831 370,386 161,445
2015 CIM 2015-2AG(4) 330,293 276,998 53,295 242,808 195,419 47,389
2015 CIM 2015-1EC 268,731 214,985 53,746 218,550 161,922 56,628
2014 CSMC 2014-CIM1(5) 333,865 268,087 65,778 220,442 159,947 60,495
2013 SLFMT 2013-2A 1,137,308 1,134,464 2,844 790,338 762,807 27,531
2013 SLFMT 2013-3A 500,390 499,139 1,251 388,541 231,315 157,226
2012 CSMC 2012-CIM1 741,939 707,810 34,129 66,939 36,307 30,632
2012 CSMC 2012-CIM2 425,091 404,261 20,830 58,313 39,252 19,061
2012 CSMC 2012-CIM3 329,886 305,804 24,082 130,090 110,649 19,441
2008 PHHMC 2008-CIM1 619,710 549,142 70,568 51,587 37,459 14,128
TOTAL $16,120,846 $13,603,841 $2,517,005 $12,644,540 $10,168,215 $2,476,325
% of origination remaining 78%
(1) Contains collateral from Springleaf 2013-1A Trust.
(2) Contains collateral from Springleaf 2012-3A Trust.
(3) Contains collateral from Springleaf 2012-2A Trust.
(4) Contains collateral from Springleaf 2012-1A Trust.
(5) Contains collateral from Springleaf 2011-1A Trust.
CONSOLIDATED LOAN SECURITIZATIONS
Information is unaudited, estimated and subject to change. 6
($ in thousands) At Issuance / Acquisition March 31, 2017
Vintage Deal Total OriginalFace
Total of
Tranches
Sold
Total of
Tranches
Retained
Total Remaining
Face
Remaining
Face of
Tranches
Sold
Remaining Face
of Tranches
Retained
2014 CSMC 2014-4R(1) 367,271 — 367,271 236,725 — 236,725
2010 CSMC 2010-1R 1,730,581 691,630 1,038,951 583,487 4,992 578,495
2010 CSMC 2010-11R 566,571 338,809 227,762 250,518 39,189 211,329
2009 CSMC 2009-12R 1,730,698 915,566 815,132 536,760 102,586 434,174
2009 JPMRR 2009-7 1,522,474 856,935 665,539 501,750 140,218 361,532
2009 JMAC 2009-R2 281,863 192,500 89,363 88,922 31,904 57,018
TOTAL 6,199,458 2,995,440 3,204,018 2,198,162 318,889 1,879,273
% of origination remaining 35% 11% 59%
CONSOLIDATED RMBS SECURITIZATIONS
▪ Re-Remic subordinate bonds have had slow prepayments considering the low interest rate environment
▪ Chimera expects the subordinate bond portfolio to have meaningful impact on earnings for the foreseeable future
(1) Contains collateral from CSMC 2010-12R Trust.
Information is unaudited, estimated and subject to change. 7
Agency Securities – As of March 31, 2017
Repo Days to Maturity – As of March 31, 2017
Agency Securities – As of December 31, 2016
Repo Days to Maturity – As of December 31, 2016
Maturity PrincipalBalance
Weighted
Average Rate
Weighted
Average Days
Within 30 days $1,886,437 0.87%
30 to 59 days 700,615 0.97%
60 to 89 days 267,663 0.93%
90 to 360 days 233,019 0.93%
Over 360 days — —
Total $3,087,734 0.90% 32 Days
(1) Coupon is a weighted average for Commercial and Agency IO
(2) Notional Agency IO was $3.2 billion and $3.4 billion as of March 31, 2017 and December 31, 2016 respectively.
Security
Type Coupon
(1) Current
Face
Weighted
Average
Market Price
Weighted
Average CPR
Agency
Pass-
through
3.50% $1,001,123 102.5 11.0
4.00% 1,207,431 105.1 15.3
4.50% 271,980 107.5 21.3
Commercial 3.6% 1,393,290 99.2 —
Agency IO 0.8% N/M(2) 4.0 7.3
Total $3,873,824
Maturity PrincipalBalance
Weighted
Average Rate
Weighted
Average Days
Within 30 days $2,203,298 0.95%
30 to 59 days 653,210 0.94%
60 to 89 days 192,418 1.03%
90 to 360 days 10,341 1.00%
Over 360 days — —
Total $3,059,267 0.95% 23 Days
Security
Type Coupon
(1) Current
Face
Weighted
Average
Market Price
Weighted
Average CPR
Agency
Pass-
through
3.50% $1,036,300 102.4 18.3
4.00% 1,266,884 105.1 23.3
4.50% 291,385 107.5 24.2
Commercial 3.6% 1,331,544 98.9 0.2
Agency IO 0.8% N/M(2) 4.3 26.4
Total $3,926,113
AGENCY & REPO SUMMARY
Information is unaudited, estimated and subject to change. 8
Description
($ in thousands)
- 100 Basis
Points
- 50 Basis
Points Unchanged
+50 Basis
Points
+100 Basis
Points
Agency
Securities
Market Value $ 4,330,594 $ 4,220,920 $ 4,101,851 $ 3,976,033 $ 3,847,031
Percentage Change 5.6 % 2.9 % - (3.1)% (6.2)%
Swap
Market Value (104,384) (51,009) - 49,365 97,693
Percentage Change (2.5)% (1.2)% - 1.2 % 2.4 %
Futures
Market Value (35,537) (17,525) - 17,059 33,662
Percentage Change (0.9)% (0.4)% - 0.4 % 0.8 %
Net Gain/(Loss) $ 88,822 $ 50,535 - $ (59,394) $ (123,465)
Percentage Change
in Portfolio Value(1) 2.2 % 1.2 % - (1.4)% (3.0)% Near Term 0-3
Short Term 3-5
Medium Term 5-10
Long Term 10-30
Hedge Book Maturities
3%
34%
57%
6%
INTEREST RATE SENSITIVITY
Chimera continues to reduce its rate exposure by reducing its Agency portfolio and hedges
Total Notional Balance - Derivative Instruments
March 31, 2017 December 31, 2016
Interest Rate Swaps 1,535,900 1,396,900
Swaptions 482,000 624,000
Futures 619,700 619,700
(1) Based on instantaneous moves in interest rates.
chimerareit.com